# Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)

> **NCT06621888** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fenix Innovation Group** · enrollment: 18 (actual)

## Conditions studied

- PANS Pediatric Acute-Onset Neuropsychiatric Syndrome

## Interventions

- **DRUG:** NTI164

## Key facts

- **NCT ID:** NCT06621888
- **Lead sponsor:** Fenix Innovation Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-02
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06621888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06621888, "Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06621888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*